VCP
REGN icon

Verus Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Verus Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-320
Closed -$228K – 397
2024
Q4 		$228K Sell
320
-20
-6% -$16.8K 0.02% 325
2024
Q3 		$357K Buy
340
+12
+4% +$13.4K 0.03% 238
2024
Q2 		$345K Buy
328
+2
+0.6% +$1.94K 0.04% 242
2024
Q1 		$314K Buy
326
+67
+26% +$63.7K 0.03% 251
2023
Q4 		$227K Sell
259
-26
-9% -$21.4K 0.03% 283
2023
Q3 		$235K Sell
285
-5
-2% -$3.93K 0.03% 254
2023
Q2 		$208K Sell
290
-30
-9% -$23.1K 0.03% 274
2023
Q1 		$263K Buy
+320
New +$241K 0.04% 232
2022
Q4 		– Sell
-375
Closed -$258K – 287
2022
Q3 		$258K Sell
375
-50
-12% -$31.5K 0.05% 221
2022
Q2 		$252K Sell
425
-135
-24% -$87.8K 0.05% 239
2022
Q1 		$364K Buy
+560
New +$354K 0.06% 226
2020
Q1 		$38K Sell
78
-162
-68% -$66.8K 0.01% 584
2019
Q4 		$90K Buy
+240
New +$80.7K 0.03% 409

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Verus Capital Partners's REGN Position: Q1 2025 in Review

Verus Capital Partners sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 320 shares — an estimated $228K sold.

Verus Capital Partners first reported a position in REGN in Q4 2019 and held it in 13 quarters. The position peaked at $364K in Q1 2022. 1,292 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Verus Capital Partners reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Verus Capital Partners sold 320 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $228K.
  • Verus Capital Partners first reported a position in Regeneron Pharmaceuticals in Q4 2019 and held it in 13 quarters.
  • Verus Capital Partners's Regeneron Pharmaceuticals position peaked at $364K in Q1 2022.
  • 1,292 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Verus Capital Partners's 13F filing for Q1 2025, filed 13 May 2025.